CN1056755C - Medicine of curing hepatitis - Google Patents
Medicine of curing hepatitis Download PDFInfo
- Publication number
- CN1056755C CN1056755C CN94118275A CN94118275A CN1056755C CN 1056755 C CN1056755 C CN 1056755C CN 94118275 A CN94118275 A CN 94118275A CN 94118275 A CN94118275 A CN 94118275A CN 1056755 C CN1056755 C CN 1056755C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- parts
- medicine
- grams
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal prescription prepared by the application of matching traditional Chinese medicines for treating hepatitis and a product containing the prescription. The medicine is in the form of an oral preparation with the medicinal effect of treating hepatitis, and is prepared by matching the traditional Chinese medicines of epimedium, giant knotweed rhizome, red peony root, dandelion, astragalus root, rhubarb, ganoderma, glossy privet fruit, bushy sophora, glabrous greenbrier rhizome, etc. through extraction and concentration. The ALT normalization rate is 51.6% for chronic persistent hepatitis and 59.4% for chronic active hepatitis. The AST normalization rate is 48.4% for chronic persistent hepatitis and 62.3% for chronic active hepatitis. The inhibiting rate on HBV-DNA and DNA-P is 76.1% and 78.4% respectively. The medicine has the advantage of no toxic or side effect.
Description
What the present invention relates to is that a kind of application drug matching forms, the pharmaceutical formulation of treatment hepatitis and contain the product of this prescription.
Hepatitis B is the viral infectious of serious harm human body health, because the hepatitis B virus range of infection is wide, the easy infection number is many, wherein the hepatitis patient of 10-20% is a chronic hepatitis B, and the Drug therapy difficulty of chronic active hepatitis is big, and quite a few people will be gradually transformed into the trend of liver cirrhosis, its transformation time is that 3-10 does not wait, therefore, the treatment of chronic hepatitis B, not only to suppress virus in vivo duplicate propagation, eliminate its virus, also will recover the normal function of its liver, human body immunity improving could be blocked the badness come-off that liver cirrhosis appears in body.China adopts the prescription and the medicine of Chinese herbal treatment hepatitis B a lot, as CN1065593A, the decoct and the powder of the spirit of hepatitis B specially good effect, the production method of CN1060608A hepatitis record and CN85100392A extract the method for treatment medicine for curing hepatitis from Radix Sophorae Tonkinensis, all have their own characteristics each, but clinical case is observed and there is certain weakness in the clinical practice result, mainly is to the inhibition of hepatitis B virus and removes undesirablely, and curative effect is not high.Existing market product sold polyporusum bellatus treatment hepatitis B, the HBeAg negative conversion rate is 34.2%, and doing well,improving and SGPT normalization rate are 12.8%, 35.1%.And bifendate is used for the chronic hepatitis patient, and the ALT normalization rate is 77.4%, but the knock-on rate of ALT is higher, drug withdrawal after 3 months ALT knock-on rate reach 30-50%, and other liver function index is not had obvious improvement, clinical practice is subjected to great restriction like this.
Also has commercially available hepatitis spirit (Radix Sophorae Tonkinensis) injection, need injection every day, and the HBeAg negative conversion rate is 24%, DNA-P negative conversion rate 24.19%, total effective rate are 46.4%, because the sick particularity of planting of hepatitis, the pharmaceutical effectiveness of clinical practice at present is undesirable, the patient more is badly in need of wanting the curative effect height, and toxicity is low, oral new medicine easy to use.
Clinical practice situation according to the present world, state's internal therapy hepatitis medicament, the sick cause of disease characteristics of planting of hepatitis have been summed up, sum up effective prescription for the treatment of hepatitis for many years, systematically investigated the compatibility of Chinese crude drug medicine prescription and the peroral dosage form of production technology and optimal clinical application.
The purpose of this invention is to provide and a kind ofly can improve liver function fast, improve the hepatic pathology performance, adjust immunity of organism, eliminate hepatitis B virus, improve the active drug of the treatment hepatitis B of negative conversion rate.
The present invention is in line with the heat-clearing and toxic substances removing of the traditional Chinese medical science, and the principle of dispersing the stagnated live-QI to relieve the stagnation of QI, conditioning liver stomach, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling is carried out composition of prescription.Medicine of the present invention contains in parts by weight: Herba Epimedii 10-50 part, Rhizoma Polygoni Cuspidati 5-60 part, Radix Paeoniae Rubra 6-120 part, Herba Taraxaci 10-120 part, Radix Astragali 10-150 part, Radix Et Rhizoma Rhei 5-10 part, Ganoderma 6-30 part, Fructus Ligustri Lucidi 6-45 part, root of subprostrate sophora 5-15 part, Rhizoma Smilacis Glabrae 10-100 part.
Medicine of the present invention is to handle, batching, extract, concentrate (unfinished work check) and the oral formulations made through raw material.Promptly can be: tablet, electuary, capsule, oral liquid, syrup etc. keep the oral formulations of physiology drug effect.
Embodiment 1 (low dosage)
With 1 grammes per square metre is 1 part, and its content is: Herba Epimedii 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Paeoniae Rubra 10 grams, Herba Taraxaci 10 grams, the Radix Astragali 10 grams, Radix Et Rhizoma Rhei 5 grams, Ganoderma 10 grams, Fructus Ligustri Lucidi 8 grams, root of subprostrate sophora 5 grams, Rhizoma Smilacis Glabrae 10 grams.
Above medical material is through following PROCESS FOR TREATMENT:
(1) with the Diluted Alcohol 70-85% lixiviate of Ganoderma, Herba Epimedii, Rhizoma Smilacis Glabrae, extracting solution merges.
(2) with Herba Taraxaci, Rhizoma Polygoni Cuspidati, the Radix Astragali, root of subprostrate sophora, Fructus Ligustri Lucidi, Radix Paeoniae Rubra, Radix Et Rhizoma Rhei, add decocting in water, the water extract merges.
(3) will merge with the water extract behind the extracting solution decompression recycling ethanol in (1).Concentrating under reduced pressure becomes thick paste.
(4) with condensed cream oven dry in (3), pulverize again, cross 80 mesh sieves, be wetting agent with 60% ethanol, be controlled to granule, oven dry by 20 mesh sieves, is made electuary again, and every bag 10 restrains 1 bag/time/day.
(5) with (4) small particles electuary, be packaged into 10 gram/bags, or incapsulate, can be made into every capsules and contain 0.5 gram dose.Every day three times, each 6.
(6) or with the thick paste pressing tablet technology of (4), be pressed into 0.5 gram/sheet, tablet, four times a day, each 4.
(7) with (1), (2) extracting solution merges, and stirs evenly, and after the standing over night, the leaching supernatant reclaims ethanol, becomes concentrated solution, adds simple syrup, makes syrup preparation.
The 120ml/ bottle, every day secondary, each 20ml.
Embodiment 2 (median dose)
Get Herba Epimedii 30 grams, Rhizoma Polygoni Cuspidati 30 grams, Radix Paeoniae Rubra 60 grams, Herba Taraxaci 60 grams, the Radix Astragali 80 grams, Radix Et Rhizoma Rhei 8 grams, Ganoderma 15 grams, Fructus Ligustri Lucidi 30 grams, root of subprostrate sophora 10 grams, Rhizoma Smilacis Glabrae 60 grams.With above medical material, by process in the example 1 make electuary 10 gram/bags or capsule 0.5 gram/, or tablet 0.5 gram/sheet or syrup 120ml/ bottle.
Embodiment 3 (high dose)
Get Herba Epimedii 50 grams, Rhizoma Polygoni Cuspidati 60 grams.Radix Paeoniae Rubra 120 grams, Herba Taraxaci 120 grams, the Radix Astragali 150 grams, Radix Et Rhizoma Rhei 10 grams, Ganoderma 30 grams, Fructus Ligustri Lucidi 45 grams, root of subprostrate sophora 15 grams, Rhizoma Smilacis Glabrae 100 grams.Above medical material is made electuary by example 1 process, or capsule or tablet or syrup.
Drug standard of the present invention is all according to " Chinese pharmacopoeia requirement.
Medicine of the present invention, confirm through clinical application research and experimentation, take the medicine that contains this prescription, can suppress duck liver virus (DHBV-DNA, DNA-P) improve liver function, suppress hepatitis B virus duplication, the disposable gastric infusion LD50 of acute toxicity test in mice＞141.69 (crude drug)/kg, mice maximum tolerated dose＞247.8g (crude drug)/kg is equivalent to 112.5 times of clinical consumption.The rat long term toxicity test confirms that low dose group is 5.5 times of clinical dosage, 12g/kg.Do not have the overt toxicity reaction, substantially nontoxic, high dose group is 11 times of 24g/Kg of clinical dosage, and no pathology change and influence, through clinical research ALT normalization rate chronic persistent hepatitis is 51.6%, chronic active hepatitis 59.4%, AST normalization rate are 48.4%, 62.3%, to chronic persistent hepatitis, chronic active hepatitis HBeAg, DNA-P, HBV-DNA, negative conversion rate is respectively 46.2%, 41.2%, 41.1% and 49.1%, 55.6%, and 43.5% is remarkable with the matched group comparing difference.Duck liver virus HBV-DNA and DNA-P suppression ratio are respectively 76.1% and 78.4%, are better than matched group, and nontoxic pair of effect.
Claims (2)
1. medicine for the treatment of hepatitis is characterized in that the raw material of following row weight portion is made:
6～120 parts of 5～60 parts of Radix Paeoniae Rubra of 10～50 parts of Rhizoma Polygoni Cuspidati of Herba Epimedii
5～10 parts of 10～150 parts of Radix Et Rhizoma Rhei of 10～120 parts of Radixs Astragali of Herba Taraxaci
5～15 parts of 6～45 parts of root of subprostrate sophoras of 6～30 parts of Fructus Ligustri Lucidi of Ganoderma
10～100 parts of Rhizoma Smilacis Glabraes.
2. medicine according to claim 1 is characterized in that, this medicine is electuary, tablet, capsule, syrup or the oral liquid of handling, preparing burden, extract, concentrate, make through raw material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118275A CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94118275A CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1106690A CN1106690A (en) | 1995-08-16 |
| CN1056755C true CN1056755C (en) | 2000-09-27 |
Family
ID=5038733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94118275A Expired - Fee Related CN1056755C (en) | 1994-11-19 | 1994-11-19 | Medicine of curing hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056755C (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100239879B1 (en) * | 1997-11-05 | 2000-02-01 | 김상조 | Crude drug composition for treatment and prevention of liver cancer |
| CN100356958C (en) * | 2006-07-06 | 2007-12-26 | 张砚 | Synergistic medicinal composition for treating hepatitis |
| CN100363040C (en) * | 2006-08-17 | 2008-01-23 | 张娜 | Medicinal compositions comprising biphenyldicarboxylate |
| CN101856384B (en) * | 2009-04-09 | 2011-08-17 | 李佳柔 | Liver-protecting combination |
| CN101721597B (en) * | 2009-12-30 | 2011-12-21 | 宁波市江北威曼生物科技有限公司 | Pharmaceutical composition containing oleanolic acid |
| CN101810759B (en) * | 2010-04-27 | 2011-08-31 | 罗丹晓 | Curbitacin-containing medicine |
| CN106138260A (en) * | 2015-04-13 | 2016-11-23 | 周海腾 | A kind of Chinese medicine oral liquid treating hepatitis |
| CN107158267A (en) * | 2017-05-26 | 2017-09-15 | 蒋田英 | A kind of medicine for treating hepatitis |
| CN107802710A (en) * | 2017-11-06 | 2018-03-16 | 廖会吉 | A kind of medicine for treating hepatitis B and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078897A (en) * | 1993-01-03 | 1993-12-01 | 于灵惠 | " hepatitis B health " Chinese medicine preparation and preparation technology thereof |
| CN1089488A (en) * | 1993-08-09 | 1994-07-20 | 张经济 | Compound Chinese caterpillar fungus extract and preparation technology thereof |
-
1994
- 1994-11-19 CN CN94118275A patent/CN1056755C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078897A (en) * | 1993-01-03 | 1993-12-01 | 于灵惠 | " hepatitis B health " Chinese medicine preparation and preparation technology thereof |
| CN1089488A (en) * | 1993-08-09 | 1994-07-20 | 张经济 | Compound Chinese caterpillar fungus extract and preparation technology thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1106690A (en) | 1995-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102755594A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| KR20040012447A (en) | Herbal pharmaceutical composition for treatment of hiv/aids patients | |
| CN111249390A (en) | Forsythia-astragalus root compound preparation and preparation method and application thereof | |
| CN1056755C (en) | Medicine of curing hepatitis | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1969940A (en) | Antivirus pharmaceutical composition | |
| CN100534506C (en) | Chinese medicinal mixture for treating viral hepatitis | |
| CN1493315A (en) | Medicine for treating chronic hepatitis B | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN101036779A (en) | Composite medicine for treating hepatopathy and its preparing process | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN1176113A (en) | Compound bufonin of bufo gargarizans | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN1729992A (en) | External bath lotion for epidemic common cold due to wind-cold | |
| CN100591349C (en) | Chinese medicine for treating AIDS | |
| CN110898181A (en) | anti-AIDS medicine and its preparing method | |
| CN1903276A (en) | Medicinal composition for treating hepatitis B | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN101244186A (en) | Medicine preparation for treating hepatitis B, and method of preparing the same | |
| CN1086129C (en) | Hepatitis restoration pill | |
| CN103301380A (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN102846965A (en) | Traditional Chinese medicine preparation capable of resisting HIV and improving immunity and preparation method of traditional Chinese medicine | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |